Possibilities and Problems of Hepatoprotectors Application in Patients with Chronic Hepatitic C and Concomitamt Autoimmune Syndrome

I.Ya. Hospodarskyi, K.V. Volynets, V.V. Hrushko

Abstract


A study of clinical and biochemical parameters of hepatoprotectors efficiency in 32 patients with chronic hepatitis C without signs of cirrhosis and with concomitant autoimmune component has been carried out. A significant difference has been determined between therapeutic impact of bioflavonoid hepatoprotectors and hepatoprotectors with ornithine on indices of liver and immune system function, as well as on hepatitis C course.


Keywords


chronic hepatitis C; autoimmune syndrome; hepatoprotectors

References


Mangia A., Santoro R., Copetti M. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection // J. Hepatol. — 2013 Aug. — V. 59(2). — P. 21-8.

Shepard C.W., Finelli L., Alter M.J. Global epidemilogy of hepatitic C virus infection // Lancet Infect. Dis. — 2005. — V. 5. — P. 558-567.

Lavanchy D. Evolving epidemiology of hepatitis C virus // Clin. Microbiol. Infec. — 2011. — V. 17(2). — P. 107-115.

Hsu Y.C., Lin J.T., Ho H.J. et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients // Hepatology. — 2013 Oct 12. doi: 10.1002.

Armstrong G.L., Wasley A., Simard E.P. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 // Ann. Intern. Med. — 2006. — V. 144. — P. 705-714.

Faustini A., Colais P., Fabrizi E. et al. Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups // BMC Infect Dis. — 2010. — V. 10. — P. 97.

Ghinoi A., Mascia M.T., Puccini R. Manifestazioni autoimmuni e linfoproliferaive HCV-correlate: l’esempio della crioglobulinemia mista // G. Ital. Nefrol. — 2004. — V. 21, № 3. — P. 225-237.

Hawke R.L., Schrieber S.J., Soule T.A. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C // J. Clin. Pharmacol. — 2010. — V. 50(4). — P. 434-449.

Reddy K.R., Belle S.H. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C // Clin. Trials. — 2012. — V. 9(1). — P. 102-112.

Андрейчин М.А., Господарський І.Я., Луцук О.С. Спосіб діагностики гепатитів В і С. Деклараційний патент на винахід. — 2003. Бюл. № 11.

Paris A.J., Snapir Z., Christopherson C.D. A Polymorphism that Delays Fibrosis in Hepatitis C Promotes Alternative Splicing of AZIN1, Reducing Fibrogenesis // Hepatology. — 2011. — V. 54(6). — P. 2198-2207.

Ivanov A.V., Bartosch B., Smirnova O.A. HCV and Oxidative Stress in the Liver // Viruses. — 2013. — V. 5(2). — P. 439-469.




DOI: https://doi.org/10.22141/2308-2097.4.54.2014.82009

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru